ANI Pharmaceuticals Inc. (ANIP) Shares Down 2.1%
ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares fell 2.1% during mid-day trading on Thursday . The company traded as low as $63.34 and last traded at $63.36, with a volume of 136,460 shares changing hands. The stock had previously closed at $64.71.
A number of brokerages have recently issued reports on ANIP. Guggenheim reaffirmed a “buy” rating and set a $55.00 price target (up from $50.00) on shares of ANI Pharmaceuticals in a report on Saturday, May 7th. Oppenheimer Holdings Inc. upped their price target on ANI Pharmaceuticals from $65.00 to $71.00 and gave the company an “outperform” rating in a report on Friday, August 5th. Citigroup Inc. upgraded ANI Pharmaceuticals to an “outperform” rating and set a $65.00 price objective for the company in a research report on Tuesday, July 19th. Zacks Investment Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 6th. Finally, Standpoint Research cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 24th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $64.00.
The company has a 50 day moving average price of $62.38 and a 200 day moving average price of $48.12. The company has a market capitalization of $723.89 million and a price-to-earnings ratio of 73.88.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.34. The business earned $31.30 million during the quarter, compared to analysts’ expectations of $27.63 million. During the same quarter in the prior year, the firm earned $0.55 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 60.5% on a year-over-year basis. On average, equities analysts expect that ANI Pharmaceuticals Inc. will post $4.12 EPS for the current year.
In related news, VP Robert W. Schrepfer sold 12,500 shares of ANI Pharmaceuticals stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $67.06, for a total value of $838,250.00. Following the completion of the transaction, the vice president now owns 17,362 shares in the company, valued at approximately $1,164,295.72. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Arthur Przybyl sold 37,455 shares of ANI Pharmaceuticals stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $66.97, for a total value of $2,508,361.35. Following the completion of the transaction, the insider now owns 200,788 shares of the company’s stock, valued at approximately $13,446,772.36. The disclosure for this sale can be found here.
An institutional investor recently raised its position in ANI Pharmaceuticals stock. Schwab Charles Investment Management Inc. boosted its stake in ANI Pharmaceuticals Inc. (NASDAQ:ANIP) by 16.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,681 shares of the specialty pharmaceutical company’s stock after buying an additional 3,400 shares during the period. Schwab Charles Investment Management Inc. owned about 0.21% of ANI Pharmaceuticals worth $1,069,000 as of its most recent filing with the SEC.
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.